Cadefrecitinib
Cadefrecitinib (GLPG3667) is a reversible, ATP-competitive and orally active TYK2 inhibitor with an IC50 of 2.3 nM. Cadefrecitinib inhibits IFNα/pSTAT1, and the IC50 values in human peripheral blood mononuclear cell (PBMC) and whole blood assays are 70 nM and 623 nM, respectively. Cadefrecitinib has the potential for the study of inflammatory and autoimmune diseases[1].
Product Specifications
Product Name Alternative
GLPG3667
UNSPSC
12352005
Target
JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/glpg3667.html
Purity
99.81
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
N#CC1=NC=C(C(C)=C1)OC2=CC(NC3=NN=C(N4CCOCC4)C=C3)=C(N=CN5C)C5=N2
Molecular Formula
C22H21N9O2
Molecular Weight
443.46
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-156961/GLPG3667-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-156961/GLPG3667-SDS-MedChemExpress.pdf
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
JAK1; JAK2; JAK3; Tyk2
CAS Number
[2308520-97-8]
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Recombinant Mycoplasma genitalium Uncharacterized protein MG441 (MG441)
